Single nucleotide polymorphism in ABCG2 is associated with irinotecan-induced severe myelosuppression.
about
Exploring the distribution of genetic markers of pharmacogenomics relevance in Brazilian and Mexican populationsRole of the lean body mass and of pharmacogenetic variants on the pharmacokinetics and pharmacodynamics of sunitinib in cancer patients.Association between the low-dose irinotecan regimen-induced occurrence of grade 4 neutropenia and genetic variants of UGT1A1 in patients with gynecological cancers.Virtual Clinical Studies to Examine the Probability Distribution of the AUC at Target Tissues Using Physiologically-Based Pharmacokinetic Modeling: Application to Analyses of the Effect of Genetic Polymorphism of Enzymes and Transporters on IrinotecPharmacogenetics research on chemotherapy resistance in colorectal cancer over the last 20 yearsEfflux transporter variants as predictors of drug toxicity in lung cancer patients: systematic review and meta-analysis.Drug transport by breast cancer resistance protein.Ethnic differences in the metabolism, toxicology and efficacy of three anticancer drugs.Pharmacogenetics of drug transporters in the enterohepatic circulation.ABCG2 transporter: therapeutic and physiologic implications in veterinary species.An update on ethnic differences in drug metabolism and toxicity from anti-cancer drugs.Pharmacogenomics and metastatic colorectal cancer: current knowledge and perspectives.Effect of the ATP-binding cassette transporter ABCG2 on pharmacokinetics: experimental findings and clinical implications.Individualized therapy for metastatic colorectal cancer.Platinum-based chemotherapy: gastrointestinal immunomodulation and enteric nervous system toxicity.Influx transporter variants as predictors of cancer chemotherapy-induced toxicity: systematic review and meta-analysis.Reverse Translational Research of ABCG2 (BCRP) in Human Disease and Drug Response.Interindividual regulation of the BCRP/ABCG2 transporter in term human placentas.Pharmacogenetics of Adverse Drug Reactions
P2860
Q28545128-F1ECF8FB-6E35-4325-A2C6-715943C621BAQ33418378-0E621615-F5E2-4D3B-BC96-0006EBB2A3E3Q33727738-038C743E-EF53-4064-BB6A-0514B9A64B01Q33875931-F41A4B0A-0F74-4FF4-9E0D-D64217527DC2Q34008793-E837EEFD-8100-44D9-9838-51C71F039098Q36043023-EF3B7485-1F4C-4E93-B777-68C39AB320EBQ37793056-D822AD77-AABD-4841-9B23-97421BAB7CE7Q37876401-E2EBC819-AC7D-49DB-80F9-7B6B5546BABFQ37880875-84AE23AF-5BC3-40B6-9E6A-B79B0043F80CQ37885400-F9F9198D-8F5F-4C4E-A13B-8DF47A26DF7DQ37939200-FA73A27D-5D1E-46BD-B3FE-2DFBB4E1576EQ37969851-A79F32C1-95E5-49AD-A3F4-8C0584FA7DC4Q38071700-3EF042F1-E632-42B5-BE63-28D6215B27B3Q38092886-2C1B8383-5EE7-4DF6-98FE-906DD032B5D9Q38287054-167B37C3-F882-45B7-B8B7-6DF106EA45FFQ38845004-ACB400BA-8813-4F62-880A-7CCC077C671DQ46109720-A2986459-1E96-44B2-97DD-35F38C955EF1Q49546188-03C4C044-1097-4825-A0B3-C9AAB71917F6Q57302675-01243EF5-DB01-4974-85E1-8EEAEB055CD2
P2860
Single nucleotide polymorphism in ABCG2 is associated with irinotecan-induced severe myelosuppression.
description
2009 nî lūn-bûn
@nan
2009年の論文
@ja
2009年学术文章
@wuu
2009年学术文章
@zh
2009年学术文章
@zh-cn
2009年学术文章
@zh-hans
2009年学术文章
@zh-my
2009年学术文章
@zh-sg
2009年學術文章
@yue
2009年學術文章
@zh-hant
name
Single nucleotide polymorphism ...... duced severe myelosuppression.
@en
Single nucleotide polymorphism ...... duced severe myelosuppression.
@nl
type
label
Single nucleotide polymorphism ...... duced severe myelosuppression.
@en
Single nucleotide polymorphism ...... duced severe myelosuppression.
@nl
prefLabel
Single nucleotide polymorphism ...... duced severe myelosuppression.
@en
Single nucleotide polymorphism ...... duced severe myelosuppression.
@nl
P2093
P2860
P356
P1476
Single nucleotide polymorphism ...... duced severe myelosuppression.
@en
P2093
Hiromasa Harada
Hitoshi Zembutsu
Kazuaki Sasaki
Koichi Hirata
Noriyuki Shinoda
Pei-Chieng Cha
Rai Shimoyama
Shunji Kawamoto
Taisei Mushiroda
Tomohisa Furuhata
P2860
P2888
P304
P356
10.1038/JHG.2009.80
P577
2009-08-21T00:00:00Z